Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933220 | 0.84 | KDM4E (0.37) | KDM4ECYP2A13MEN1KMT2AALDH1A1 | |
| SCHEMBL23933219 | 0.84 | KDM4E (0.37) | KDM4ECYP2A13MEN1KMT2AALDH1A1 | |
| SCHEMBL15922897 | 0.82 | TP53 (0.41) | KDM4EMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL11355878 | 0.77 | HSD11B1 (0.41) | MEN1KMT2AMAPK1SIGMAR1TP53 | |
| SCHEMBL15922741 | 0.77 | TP53 (0.39) | MEN1KMT2AMAPK1SIGMAR1TP53 | |
| SCHEMBL1143530 | 0.75 | TP53 (0.41) | MEN1KMT2AALDH1A1MAPK1SIGMAR1 | |
| SCHEMBL15922928 | 0.75 | HSD11B1 (0.43) | MEN1KMT2ATP53SMN1; SMN2TSHR | |
| SCHEMBL10436532 | 0.75 | HSD11B1 (0.43) | MEN1KMT2ATP53SMN1; SMN2TSHR | |
| SCHEMBL25044952 | 0.73 | CYP2A13 (0.38) | KDM4ECYP2A13ALDH1A1EPHX2SMN1; SMN2 | |
| SCHEMBL455945 | 0.72 | TP53 (0.36) | KDM4EMEN1KMT2AALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-08-18 | — | — | US | disclosed |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | KDM4E 2982/4885CYP2A13 4715/4885MEN1 3151/4885 |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | KDM4E 3465/4885CYP2A13 1288/4885MEN1 2260/4885 |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | KDM4E 3465/4885CYP2A13 1288/4885MEN1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.